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Rezumat
Afecţiuni hepatice mimate de boala Wilson
Boala Wilson este o maladie determinată genetic rară ca 
prevalenţă, dar şi rar diagnosticată de specialişti prin 
insufi cienta recunoaştere a acestei maladii, precum şi prin 
mimarea altor afecţiuni hepatice în cadrul acestei boli 
genetice. 
Deseori, hepatita autoimună sau steatohepatita nealcoolică 
este confundată cu boala Wilson, prin tablou clinic 
asemănător, precum şi prin teste de diagnostic care de 
asemenea se pot modifi ca în aceste patologii (reducerea 
ceruloplasminei, sporirea cuprului în urină pot fi  întâlnite 
şi în alte afecţiuni hepatice decât în boala Wilson). 
Odată suspectată, boala Wilson necesită să fi e confi rmată 
prin testul genetic (mutaţiile din cadrul genei ATP7B) sau 
prin biopsie hepatică cu examen histochimic.
Cuvinte-cheie: boala Wilson, afecţiuni hepatice mimate, 
test genetic, biopsie hepatică
Резюме
Мимические заболевания печени при болезни 
Вильсона
Болезнь Вильсона oтносится к редким заболеваниям. 
Картина хронического гепатита при болезни Вильсона 
схожа с клинической картиной других нозологических 
форм  гепатита ,  что  требует  исключения 
болезни Вильсона у всех больных с хроническим 
гепатитом, особенно у молодых больных и в случаях 
сочетания поражения печени с неврологической 
симптоматикой. 
Диагноз подтверждаeтcя низкой концентрациeй 
церулоплазмина в сыворотке и увеличением суточной 
экскреции меди с мочой, которые возможны также при 
других заболеваниях печени (аутоиммунный гепатит, 
хронические активные заболевания печени, холестаз, 
острая печеночная недостаточность другого генеза), 
у некоторых гетерозиготных носителей мутации 
болезни Вильсона. 
Несомненно ,  генетические  тесты  способны 
точно подтвердить диагноз, однако, учитывая 
генетическую вариантность, исследование становится 
необоснованным с экономической позиции.
Ключевые слова: болезнь Вильсона, мимические 
заболевания печени, генетический тест, биопсия
Introduction
Wilson’s disease is listed as a “rare disease” by 
the Office of Rare Diseases of the National Institu-
tes of Health. Worldwide, the incidence of Wilson’s 
disease is 10-30 million cases, and the heterozygote 
carrier rate is 1 case per 100 persons, with the gene-
tic mutation frequency varying from 0.3-0.7%. The 
prevalence of Wilson disease is 1 per 30,000 indivi-
duals. In general, the upper age limit for considering 
Wilson’s disease is 40 years and the lower age limit 
is 5 years, although the disorder has been detected 
in children younger than 3 years and in adults older 
than 70 years [1]. 
Since the copper accumulation occurs in the 
liver initially, the disease often starts with hepatic 
symptoms; therefore, during childhood and the 
teenage years it is the most common manifestation. 
The liver involvement may range from mild hepati-
tis, fulminate hepatic failure to chronic hepatitis and 
cirrhosis [2].
Clinical peculiarities in Wilson disease
• One fourth of all Wilson patients experienced
sometime in their lives an acute episode of he-
patitis, presenting with non-specific symptoms 
(malaise, anorexia, epigastric pain, jaundice,
elevated LFT) without viral markers or history
of a toxic agent [1, 3].
• It is important to rule out Wilson disease in ca-
ses with non- viral acute hepatitis, especially if
mild hemolysis and low uric acid level are also
present.
• Fulminate hepatitis is a relatively rare, severe
disease, which is often lethal. It usually occurs
during the teenage years or young adulthood
with symptoms of rapidly progressing acute
hepatitis (deep icterus, encephalopathy, blee-
ding disorders, terminal renal failure, hepatic
coma [5].
• Chronic hepatitis is the most common liver
pathology in WD.
• The liver biopsy specimen reveals non-specific
changes of chronic inflammation, intranuclear
glycogen and periportal steatosis. The staining
of the copper associated protein is usually positi-
ve. Measurement of the hepatic copper content 
aids in establishing the definitive diagnosis.
The recognition of Wilson disease is often the
process of exclusion of more common causes (e.g., 
viruses, alcohol, autoimmunity), it is important to 
emphasize that awareness of the clinical features 
of these metabolic liver diseases should promote a 
proactive diagnostic evaluation [1, 6].
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Table 1
Differential diagnoses of Wilson disease in patients with 
hepatic manifestation
Condi-
tion
Differentiating signs/ symptoms Differentiating 
tests
Viral 
hepatitis 
B, C 
Patients with viral hepatitis 
may have a history of a febrile 
illness or blood transfusion, but 
otherwise the symptoms and 
signs may be identical.
Serological 
marchers for 
HBV or HCV
Haemo-
chroma-
tosis 
Patients with haemochromatosis 
may present with other features 
such as diabetes, skin pigmen-
tation, arthritis, impotence in 
males, and cardiac enlargement 
with or without symptoms and 
signs of heart failure.
Iron parameters 
and liver biopsy 
are diagnostic.
Alpha-1 
antit-
rypsin 
defi -
ciency 
Patients with alpha-1 antitrypsin 
defi ciency may have chronic 
lung disease such as emphysema 
occurring earlier than expected 
(in the 40- to 50-year-old age 
group) as well as liver disease.
Tests show that 
enzyme is defi -
cient
Autoim-
mune 
hepatitis 
Patients may have other associ-
ated autoimmune conditions and 
will respond to steroid therapy. 
However, Wilson’s disease 
should be excluded before this 
diagnosis is assumed
Patients may 
have a positive 
autoantibody 
screen including 
ANA, ASMA, 
anti-LKM and 
others.
Steato-
hepatitis 
Patients with steatohepatitis tend 
to be obese with clinical features 
of hepatitis. Wilson’s disease 
should be excluded before this 
diagnosis is assumed
Fatty liver and 
infl ammation on 
biopsy. 
Alcoholic 
cirrhosis 
Patients may have a history and 
signs of alcohol excess. Wilson’s 
disease should be excluded 
before this diagnosis is assumed, 
even if the patient drinks.
None.
Hae-
molytic 
anaemia 
If hepatic bouts are severe in 
Wilson’s disease then haemo-
lysis may occur. Haemolysis in 
the presence of liver disease in 
a person aged <40 years should 
prompt testing for Wilson’s 
disease
Tests for alter-
native causes 
of haemolytic 
anaemia, includ-
ing Coombs 
antibody, Hb 
electrophoresis 
for HbS, and 
autoantibody 
screening for 
autoimmune 
diseases.
Masks from other liver disease in Wilson disease
The clinical presentations of Wilson’s disease 
can mimic other liver disease: autoimmune hepatitis 
(especially in younger patients), nonalcoholic fatty 
liver disease, acute hepatic failure [3, 4].
• Patients in the pediatric age bracket who 
present a clinical picture of autoimmune hepatitis 
should be investigated for WD.
• Adult patients with atypical autoimmune 
hepatitis or who respond poorly to standard corticost-
eroid therapy should also be investigated for WD.
• WD should be considered in the differential 
diagnosis of patients presenting with nonalcoholic 
fatty liver disease or who have pathologic findings 
of nonalcoholic steatohepatitis. 
• WD should be suspected in any patient 
presenting with acute hepatic failure with Coombs-
negative intravascular hemolysis, modest elevations 
in serum aminotransferases, or low serum alkaline 
phosphatase and ratio of alkaline.
The differentiation of Wilson’s disease from 
autoimmune hepatitis (AIH) can be supported by 
the presence of a Kayser -Fleischer ring and throu-
gh urine and serum copper studies in patients with 
Wilson’s disease. Because the onset of fulminant 
hepatic failure (FHF) may be the first presentation 
of Wilson’s disease (WD) and autoimmune hepati-
tis (AIH) in previously asymptomatic adolescents, 
determination of the etiology of FHF is critical as 
treatment and prognosis differ between these two 
entities. Patients with AIH may be salvaged by medi-
cal treatment. On the contrary, liver transplantation 
is currently the only lifesaving therapeutic option 
available for patients with WD who present with 
fulminant liver failure. To establish the diagnosis of 
WD and AIH in the setting of FHF remains challen-
ging for diagnosticians and decisions regarding liver 
transplantation may be necessary before a diagnosis 
is firmly established [3, 5].
Differential diagnosis of NASH is important, and 
led to the confirmation of Wilson’s disease. Patients 
with NASH often present with few or no symptoms, 
though imaging techniques and liver biopsy show 
fat accumulation in the liver, mostly accompanied 
by hyperlipidemia. However, evaluation of patients 
based on fatty liver, hyperlipidemia, and abnormal 
liver function tests may not be sufficient in detecting 
the severity of the underlying cause. Therefore, for 
the adult and even elderly patients with unexplained 
histologic findings of steatohepatitis, it is reasonable 
to consider the possibility of Wilson’s disease, before 
starting any treatment regimen [1, 4].
Laboratory diagnosis
• Classically, serum ceruloplasmin concentrati-
ons are very low in parallel with low serum copper le-
vels. Though serum ceruloplasmin estimation alone 
is not specific enough to diagnose Wilson’s disease, 
concentrations as low as in this case are unusual for 
any other diagnosis. Ceruloplasmin synthesis can be 
modestly reduced in decompensated liver disease 
of any etiology or in acute liver failure. Protein losing 
enteropathy, nephrotic syndrome, and malnutrition 
will also reduce serum concentrations. Conversely, 
as its synthesis can be stimulated by estrogens and 
it is an acute phase reactant, patients taking oral 
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contraceptives or those with acute inflammatory 
change within the liver may have normal serum 
levels [2, 3].  
•  A 24 hour copper estimation is a simple and 
useful confirmatory test with raised values (>100 
μg/24 hours) invariably seen in symptomatic WD. 
Concentrations in this case were greatly raised. 
• A liver biopsy, in itself, may not be diagnostic
but is helpful in determining the extent of hepatic 
involvement and whether or not there is establi-
shed fibrosis and moderate inflammatory change 
and copper accumulation in the hepatic tissue be 
consistent with Wilson’s disease. 
• The sequence analysis of ATP7B gene (WD
gene) to identify the mutations is clinically available 
as a test. Although this is the most updated and thoro-
ugh test, that some alterations such as large deletion 
or duplication may not be detected with this method. 
It is important that the biochemical testing must be 
performed prior to genetic tests [1, 4, 5].
Table 2 
Modification the level of ceruloplasmin and urine cooper in 
liver disease
Level of ceruloplasmin can be 
decreased in:
The 24 hours urine 
cooper can be increased 
in:
Severe liver disease of any cause
Wilson disease
Heterozygote carriers from ATP7B 
Protein losing enteropathy
Aceruloplasminemia 
Menke’s disease
Nutrition copper defi ciency
Proteinuria
Chronic active hepatitis
Biliary primary cirrhosis 
Primary sclerosing 
cholangitis 
Autoimmune hepatitis 
Proteinuria 
Rheumatoid arthritis 
Treatment
• The two main treatment options are chelati-
on treatment with penicillamine or referral to a liver 
unit for consideration for orthotopic liver transplant 
(OLT). 
• Chelation therapy is the treatment of choi-
ce in patients with compensated liver disease. The 
usual starting dose of D-penicillamine is 250 mg 
daily increasing over a period of a few weeks to an 
eventual maintenance dose of 1.5 g daily. Trientine 
is an alternative chelating agent which may be used 
in those unable to take penicilamine. Elemental 
zinc inhibits gastrointestinal copper absorption but 
its long term effectiveness is unproven. Success of 
therapy is judged by clinical improvement [3, 4].
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